NasdaqGM - Delayed Quote USD

Loncar Cancer Immunotherapy ETF (CNCR)

13.95 -0.28 (-1.97%)
At close: 4:00 PM EDT

Performance Overview: CNCR

Trailing returns as of 4/24/2024. Category is Health.

YTD Return

CNCR
5.64%
Category
6.33%

1-Year Return

CNCR
10.31%
Category
11.04%

3-Year Return

CNCR
20.61%
Category
0.38%

Trailing Returns (%) Vs. Benchmarks

Monthly Total Returns
CNCR
Category
YTD
22.85%
6.33%
1-Month
-3.14%
1.19%
3-Month
22.85%
6.33%
1-Year
38.15%
11.04%
3-Year
-15.70%
-0.38%
5-Year
-3.03%
7.51%
10-Year
0.00%
9.04%
Last Bull Market
0.00%
0.00%
Last Bear Market
0.00%
0.00%

Annual Total Return (%) History

Year
CNCR
Category
2023
-1.89%
3.22%
2022
-42.31%
-15.16%
2021
-19.14%
6.88%
2020
36.52%
27.63%
2019
24.19%
26.23%
2018
-20.62%
-0.40%
2017
13.57%
24.31%
2016
-25.62%
-10.60%

ETF Summary

The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.

ETF Overview

Category Health
Fund Family Loncar Investments
Net Assets 28.75M
YTD Daily Total Return 5.64%
Yield 0.00%
Legal Type Exchange Traded Fund

Related Tickers